Windtree Therapeutics, Inc. (WINT) Financial Ratios
30 years of historical data (1995–2024) · Healthcare · Biotechnology
EV/EBITDA
N/A
—
5yr avg: N/A
P/FCF
N/A
—
5yr avg: N/A
P/B Ratio
↓
0.00
↓-100% vs avg
5yr avg: 0.71
30Y Low0.1·High1.9
ROE
↓
-82.0%
↓+41% vs avg
5yr avg: -139.8%
30Y Low-402%·High-38%
Debt/EBITDA
N/A
—
5yr avg: N/A
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
WINT Valuation Multiples
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
Windtree Therapeutics, Inc. currently has a negative P/E ratio, indicating the company is operating at a loss on a trailing-twelve-month basis.
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $1057 | $918625 | $3M | $5M | $40M | $80M | $139M | $22M | $5M | $3M | $3M |
| Enterprise Value | $44057 | $961625 | $15M | $1M | $20M | $67M | $123M | $19M | $18M | $22M | $-10722003 |
| P/E Ratio → | -0.00 | — | — | — | — | — | — | — | — | — | — |
| P/S Ratio | — | — | — | — | — | — | 704.15 | 12.46 | 3.05 | 1.47 | 3.04 |
| P/B Ratio | 0.00 | 0.09 | 0.82 | 0.53 | 0.95 | 1.15 | 1.86 | 0.68 | — | — | 1.00 |
| P/FCF | — | — | — | — | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
WINT EV Ratios
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | — | — | — | — | — | 622.00 | 10.66 | 11.93 | 10.98 | -10.86 |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — | — | — | — | — |
WINT Profitability
Margins and return-on-capital ratios measuring operating efficiency
A negative ROE of -82.0% indicates the company is currently destroying shareholder equity.
Margins
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | — | — | — | — | — | — | 93.6% | -490.7% | -1070.1% | 87.5% | 5.9% |
| Operating Margin | — | — | — | — | — | — | -12572.2% | -905.8% | -1518.4% | -1862.7% | -4035.9% |
| Net Profit Margin | — | — | — | — | — | — | -13876.3% | -1148.4% | -1242.2% | -1933.9% | -5589.7% |
Return on Capital
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -82.0% | -82.0% | -302.8% | -151.1% | -121.4% | -41.9% | -38.4% | -92.9% | — | — | -401.7% |
| ROA | -18.2% | -18.2% | -57.7% | -69.6% | -72.1% | -26.1% | -23.1% | -33.5% | -282.8% | -146.1% | -120.1% |
| ROIC | -144.7% | -144.7% | -119.5% | -142.4% | -123.5% | -39.5% | -30.2% | -44.8% | — | — | — |
| ROCE | -99.0% | -99.0% | -54.9% | -78.5% | -87.5% | -27.8% | -23.7% | -35.8% | — | -256.9% | -109.2% |
WINT Leverage & Debt
Solvency and debt-coverage ratios — lower is generally safer
Net debt stands at $43000 ($2M total debt minus $2M cash).
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.18 | 0.18 | 4.96 | 0.23 | 0.43 | 0.05 | 0.08 | 0.12 | — | — | 3.02 |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | 0.00 | 3.69 | -0.39 | -0.46 | -0.19 | -0.22 | -0.05 | — | — | -1.66 |
| Net Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — | — | — | — | — | — |
| Interest Coverage | -106.46 | -106.46 | -350.78 | -779.87 | -677.89 | -242.54 | -50.29 | -11.49 | -12.10 | -15.11 | -8.69 |
WINT Liquidity & Efficiency
Short-term solvency ratios and asset-utilisation metrics
The current ratio of 0.45x is below 1.0, meaning current liabilities exceed current assets. The current ratio has declined from 3.00x to 0.45x over the past 3 years.
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 0.45 | 0.45 | 1.35 | 3.00 | 4.77 | 2.96 | 3.05 | 1.24 | 0.19 | 0.54 | 3.69 |
| Quick Ratio | 0.45 | 0.45 | 1.35 | 3.00 | 4.77 | 2.96 | 3.05 | 1.24 | 0.19 | 0.54 | 3.69 |
| Cash Ratio | 0.31 | 0.31 | 1.08 | 2.51 | 4.54 | 2.76 | 2.89 | 1.22 | 0.15 | 0.42 | 3.50 |
| Asset Turnover | — | — | — | — | — | — | 0.00 | 0.01 | 0.44 | 0.21 | 0.02 |
| Inventory Turnover | 98.93 | — | — | — | — | — | — | — | — | — | — |
| Days Sales Outstanding | — | — | — | — | — | — | — | — | — | — | — |
WINT Shareholder Yields
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Windtree Therapeutics, Inc. returns 100.0% to shareholders annually primarily through dividends.
Dividends
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | 100.0% | 71.5% | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
Total Shareholder Return Metrics
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Total Shareholder Yield | 100.0% | 71.5% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Shares Outstanding | — | $52583 | $4306 | $700 | $550 | $348 | $243 | $33 | $8 | $3 | $3 |
Peer Comparison
Compare WINT with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
 WINTYou | $1057 | -0.0 | — | — | — | — | -82.0% | -144.7% | — |
 CRVS | $1B | -27.5 | — | — | — | — | -32.6% | -78.1% | — |
 NKTR | $2B | -8.6 | — | — | 100.0% | -236.8% | -217.9% | -57.2% | — |
 AGIO | $2B | -3.9 | — | — | 78.7% | -873.9% | -30.2% | -26.3% | — |
 PRTA | $567M | -2.3 | — | — | 61.8% | -1905.8% | -63.6% | -2099.8% | — |
 ACAD | $4B | 9.9 | 26.9 | 36.7 | 91.7% | 9.8% | 39.9% | 10.0% | 0.4 |
 INVA | $2B | 6.9 | 8.1 | 9.9 | 72.3% | 38.5% | 29.1% | 14.2% | 1.3 |
 INSM | $23B | -16.3 | — | — | 79.4% | -194.0% | -249.3% | -86.5% | — |
 MRK | $277B | 15.4 | 10.7 | 22.4 | 72.0% | 36.2% | 36.9% | 22.0% | 1.7 |
 PFE | $151B | 19.5 | 10.7 | 16.6 | 70.3% | 24.7% | 8.9% | 7.5% | 3.3 |
 ABBV | $358B | 85.5 | 15.0 | 20.1 | 70.2% | 32.8% | 6214.7% | 23.9% | 2.4 |
| Healthcare Median | — | 22.3 | 14.4 | 18.5 | 63.9% | -5.2% | -33.7% | -11.2% | 3.3 |
Peer selection based on competitive and market overlap. Compare multiple stocks →
Download Financial Ratios Data
Includes 30+ ratios · 30 years · Updated daily
See WINT's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs WINT Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare WINT vs CRVS
Side-by-side business, growth, and profitability comparison vs Corvus Pharmaceuticals, Inc..
Start ComparisonWINT — Frequently Asked Questions
Quick answers to the most common questions about buying WINT stock.
What is Windtree Therapeutics, Inc.'s P/E ratio?
Windtree Therapeutics, Inc.'s current P/E ratio is -0.0x. This places it at the 50th percentile of its historical range.
What is Windtree Therapeutics, Inc.'s ROE?
Windtree Therapeutics, Inc.'s return on equity (ROE) is -82.0%. The historical average is -171.0%.
Is WINT stock overvalued?
Based on historical data, Windtree Therapeutics, Inc. is trading at a P/E of -0.0x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
What is Windtree Therapeutics, Inc.'s dividend yield?
Windtree Therapeutics, Inc.'s current dividend yield is 100.00%.